NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









IPRASENSE

IPRASENSE

Private
ClapiersHealthcare & Life Scienceshttps://www.iprasense.com/

Last Round

Grant

Nov 1, 2021

Total Funding Raised

$1.89M

Company Overview

IPRASENSE is a life sciences company that develops and commercializes innovative cell culture monitoring equipment, including automated cell counters and viability analyzers.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Medical Imaging, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Application

Keywords

cell culture monitoringlive-cell imagingautomated cell counterlabel-free imaginglensless imagingdigital holographic microscopycell viability analysisholographic imagingbioprocess controlhigh-throughput screeningprocess analytical technologyPATbiotech equipmentdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IPRASENSE Comparables

Compare IPRASENSE with similar companies based on industry and business-model similarity.

IPRASENSE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Phase Holographic Imaging AB
81%
Aligned Genetics
79%
Nanolive SA
77%

IPRASENSE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 1, 2021
AcceleratorJul 1, 2019
GrantMay 1, 2018

IPRASENSE Investors

Notable investors and investment history

IPRASENSE investors
InvestorRounds
Innovative Health InitiativeGrant
European CommissionGrant
SATT AxLRAccelerator
BpifranceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 2, 2025

    Monthly visitors increased 49% MoM.

  • Oct 28, 2024

    Monthly visitors grew 49% MoM, reaching 972.

IPRASENSE Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

IPRASENSE Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about IPRASENSE's valuation, stock price, and market status.

Firmographic Details

HeadquartersClapiers
Employee Range3
Year Founded2013
Last FundingNov 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.